Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Net Income Loss of -$412.78 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed a decrease of -161.3% in Net Income Loss from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Net Income Loss has declined by 1,641.3%.
- Historical annual values: Fiscal year 2025: -$412.78 million | Fiscal year 2024: $673.73 million | Fiscal year 2023: -$352.09 million | Fiscal year 2022: -$231.80 million | Fiscal year 2021: $1.60 billion | Fiscal year 2020: -$327.37 million | Fiscal year 2019: -$411.47 million | Fiscal year 2018: -$346.03 million | Fiscal year 2017: -$314.67 million | Fiscal year 2016: -$198.47 million | Fiscal year 2015: -$117.73 million | Fiscal year 2014: -$53.50 million | Fiscal year 2013: -$39.41 million | Fiscal year 2012: -$20.10 million | Fiscal year 2011: -$23.71 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: